Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure
Background Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors, and Angiotensin II Receptor Antagonists (ARBs) also have the effect of reducing serum uric acid but few studies worldwide assessed. Objective Evaluate the effectiveness of serum uric acid lowering treatment of SGLT2 inhibitors, and AR...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2024-11-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/18595.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846147232444710912 |
|---|---|
| author | Tuong Le Trong Huynh Phong Thanh Pham Hien Dieu Tran Nhan Dinh Tran Duong Van Tran Bao Lam Thai Tran Khoa Dang Dang Tran Toan Hoang Ngo Son Kim Tran |
| author_facet | Tuong Le Trong Huynh Phong Thanh Pham Hien Dieu Tran Nhan Dinh Tran Duong Van Tran Bao Lam Thai Tran Khoa Dang Dang Tran Toan Hoang Ngo Son Kim Tran |
| author_sort | Tuong Le Trong Huynh |
| collection | DOAJ |
| description | Background Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors, and Angiotensin II Receptor Antagonists (ARBs) also have the effect of reducing serum uric acid but few studies worldwide assessed. Objective Evaluate the effectiveness of serum uric acid lowering treatment of SGLT2 inhibitors, and ARB in heart failure (HF) patients. Methods We conducted a cross-sectional analysis study with 8 weeks of follow-up on 733 heart failure (HF) patients treated at Can Tho Central General Hospital from January 2023 to March 2024. Patients enrolled in the study were examined and received losartan (Group A) or dapagliflozin (Group B) monotherapy or losartan and dapagliflozin combined therapy (Group C). The uric acid concentration group was defined into three subgroups with tertile 1 from smallest to quartile (Q) 1, tertile 2 from Q2 to Q3, and tertile 3 from Q3 to the largest value. Results After 8 weeks of treatment, the uric acid reduction effect between groups A, B, and C showed that the combination group had the optimal reducing effect compared to losartan and dapagliflozin monotherapy with the mean difference being −229.62 ± 76.65 µmol/L, −217.00 ± 146.17 µmol/L, and −284.43 ± 136.32 µmol/L, respectively. In total, combination therapy showed the best reduction outcome in the population of male, female, patients with type 2 diabetes mellitus (T2DM), and dyslipidemia with the mean difference ranging from −226.21 ± 74.65 µmol/L to −231.85 ± 76.28 µmol/L and −209.62 ± 184.94 µmol/L to −225.75 ± 78.53 µmol/L and −273.02 ± 204.54 µmol/L to −308.93 ± 72.97 µmol/L in group A, B, and C, respectively. Conclusion The optimal therapy for reducing uric acid levels in HF patients was the combination of losartan and dapagliflozin, and the effectiveness did not change through sex, T2DM, and dyslipidemia patients. |
| format | Article |
| id | doaj-art-9cae5f68c1c34d64ac016b7289b16ca2 |
| institution | Kabale University |
| issn | 2167-8359 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | PeerJ Inc. |
| record_format | Article |
| series | PeerJ |
| spelling | doaj-art-9cae5f68c1c34d64ac016b7289b16ca22024-12-01T15:05:43ZengPeerJ Inc.PeerJ2167-83592024-11-0112e1859510.7717/peerj.18595Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failureTuong Le Trong Huynh0Phong Thanh Pham1Hien Dieu Tran2Nhan Dinh Tran3Duong Van Tran4Bao Lam Thai Tran5Khoa Dang Dang Tran6Toan Hoang Ngo7Son Kim Tran8Department of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, VietnamDepartment of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, VietnamDepartment of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, VietnamDepartment of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, VietnamDepartment of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, VietnamDepartment of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Ninh Kieu, VietnamDepartment of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Ninh Kieu, VietnamDepartment of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Ninh Kieu, VietnamDepartment of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Ninh Kieu, VietnamBackground Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors, and Angiotensin II Receptor Antagonists (ARBs) also have the effect of reducing serum uric acid but few studies worldwide assessed. Objective Evaluate the effectiveness of serum uric acid lowering treatment of SGLT2 inhibitors, and ARB in heart failure (HF) patients. Methods We conducted a cross-sectional analysis study with 8 weeks of follow-up on 733 heart failure (HF) patients treated at Can Tho Central General Hospital from January 2023 to March 2024. Patients enrolled in the study were examined and received losartan (Group A) or dapagliflozin (Group B) monotherapy or losartan and dapagliflozin combined therapy (Group C). The uric acid concentration group was defined into three subgroups with tertile 1 from smallest to quartile (Q) 1, tertile 2 from Q2 to Q3, and tertile 3 from Q3 to the largest value. Results After 8 weeks of treatment, the uric acid reduction effect between groups A, B, and C showed that the combination group had the optimal reducing effect compared to losartan and dapagliflozin monotherapy with the mean difference being −229.62 ± 76.65 µmol/L, −217.00 ± 146.17 µmol/L, and −284.43 ± 136.32 µmol/L, respectively. In total, combination therapy showed the best reduction outcome in the population of male, female, patients with type 2 diabetes mellitus (T2DM), and dyslipidemia with the mean difference ranging from −226.21 ± 74.65 µmol/L to −231.85 ± 76.28 µmol/L and −209.62 ± 184.94 µmol/L to −225.75 ± 78.53 µmol/L and −273.02 ± 204.54 µmol/L to −308.93 ± 72.97 µmol/L in group A, B, and C, respectively. Conclusion The optimal therapy for reducing uric acid levels in HF patients was the combination of losartan and dapagliflozin, and the effectiveness did not change through sex, T2DM, and dyslipidemia patients.https://peerj.com/articles/18595.pdfHeart failureLosartanDapagliflozinUric acid reductionCombination therapy |
| spellingShingle | Tuong Le Trong Huynh Phong Thanh Pham Hien Dieu Tran Nhan Dinh Tran Duong Van Tran Bao Lam Thai Tran Khoa Dang Dang Tran Toan Hoang Ngo Son Kim Tran Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure PeerJ Heart failure Losartan Dapagliflozin Uric acid reduction Combination therapy |
| title | Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure |
| title_full | Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure |
| title_fullStr | Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure |
| title_full_unstemmed | Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure |
| title_short | Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure |
| title_sort | losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure |
| topic | Heart failure Losartan Dapagliflozin Uric acid reduction Combination therapy |
| url | https://peerj.com/articles/18595.pdf |
| work_keys_str_mv | AT tuongletronghuynh losartananddapagliflozincombinationtherapyinreducinguricacidlevelcomparedtomonotherapyinpatientswithheartfailure AT phongthanhpham losartananddapagliflozincombinationtherapyinreducinguricacidlevelcomparedtomonotherapyinpatientswithheartfailure AT hiendieutran losartananddapagliflozincombinationtherapyinreducinguricacidlevelcomparedtomonotherapyinpatientswithheartfailure AT nhandinhtran losartananddapagliflozincombinationtherapyinreducinguricacidlevelcomparedtomonotherapyinpatientswithheartfailure AT duongvantran losartananddapagliflozincombinationtherapyinreducinguricacidlevelcomparedtomonotherapyinpatientswithheartfailure AT baolamthaitran losartananddapagliflozincombinationtherapyinreducinguricacidlevelcomparedtomonotherapyinpatientswithheartfailure AT khoadangdangtran losartananddapagliflozincombinationtherapyinreducinguricacidlevelcomparedtomonotherapyinpatientswithheartfailure AT toanhoangngo losartananddapagliflozincombinationtherapyinreducinguricacidlevelcomparedtomonotherapyinpatientswithheartfailure AT sonkimtran losartananddapagliflozincombinationtherapyinreducinguricacidlevelcomparedtomonotherapyinpatientswithheartfailure |